CytRx Announces the Completion of Enrollment in Its Global Phase 2b Clinical Trial of Aldoxorubicin in Patients with Second-Line Small Cell Lung Cancer
PRNewswire/ -- CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that it has reached its enrollment target of 132 patients for the company's global Phase 2b clinical trial of aldoxorubicin in patients with previously treated small cell lung cancer (SCLC). The Phase 2b study is a randomized, comparative trial being conducted at 41 sites in the United States, Hungary and Spain.
Alcon launches the NGENUITY® 3D Visualization System designed to further enhance retinal surgeon experience
Basel, Switzerland, September 8, 2016 – Alcon, the global leader in eye care and a division of Novartis, launches the NGENUITY® 3D Visualization System, a platform for Digitally Assisted Vitreoretinal Surgery (DAVS). The system is designed to enhance visualization of the back of the eye for improved surgeon experience. Alcon is launching the system in collaboration with TrueVision® 3D Surgical, a California-based company specializing in digital 3D visualization and guidance for microsurgery. The NGENUITY® 3D Visualization System allows retinal surgeons to operate looking at a high definition 3D screen, instead of bending their necks to look through the eye-piece of a microscope. Traditional vitrectomy surgeries range from 30 minutes to over three hours in length to complete. This microscope-free design is engineered to improve surgeons’ posture and may reduce fatigue.1
New Research Highlights Economic Burden of Opioid Abuse and its Associated Costs and Cost Drivers by Diagnosis at PAINWeek® 2016
STAMFORD, Conn.--(BUSINESS WIRE)--Purdue Pharma L.P. today presented results from two studies evaluating the excess healthcare costs of opioid abuse and misuse, quantifying the overall economic burden as well as individual cost drivers from a payer perspective at the 10th Annual PAINWeek® Conference in Las Vegas, Sept 6-10. The first study titled, “The economic burden of opioid abuse and its drivers: evidence from a payer perspective,” investigated the current estimates of the excess costs of opioid abuse from a payer perspective both before and after abuse diagnosis, and the drivers of these excess costs. This study analyzed claims data from approximately eight million commercially-insured patients from the Truven MarketScan Commercial Claims and Encounters Database that reported at least one diagnosis of opioid abuse, dependence, or poisoning or overdose (“Opioid Abuse”). The study found that Opioid Abuse was associated with ,470 in excess costs during the 12 months surrounding an initial Opioid Abuse episode. Excess costs began increasing well before the initial diagnosis, with non-opioid drug abuse treatment comprising a substantial proportion of the excess costs of Opioid Abuse before incident diagnosis. Moreover, 28% of the excess costs following Opioid Abuse diagnosis were driven by costs of treating non-Opioid Abuse, compared to 31% for Opioid Abuse. For more information please visit www.purduepharma.com
GenSight Biologics Receives Approval to Include Teenage Patients in RESCUE and REVERSE Phase III Trials with GS010 in Leber’s Hereditary Optic Neuropathy
GenSight Biologics (Paris: SIGHT) (Euronext: SIGHT, FR0013183985, PEA-PME eligible), a biopharma company that discovers and develops innovative gene therapies for neurodegenerative retinal diseases and diseases of the central nervous system, today announced that regulatory agencies and ethics committees in the United States, France and the United Kingdom, have authorized a protocol amendment to include teenage patients (15-18 years) in RESCUE and REVERSE, two ongoing Phase III clinical trials of GS010 in the treatment of Leber’s Hereditary Optic Neuropathy (LHON).
New analysis showed dose adjustment of Giotrif® (afatinib) improved tolerability without an apparent impact on efficacy in patients with EGFR mutation-positive non-small cell lung cancer
NGELHEIM, Germany--(BUSINESS WIRE)--Results from a new post-hoc analysis of two large Phase III trials (LUX-Lung 3 and LUX-Lung 6) assessing the impact of dose adjustments for Giotrif® (afatinib*) in patients with advanced non-small cell lung cancer (NSCLC) were published in Annals of Oncology. The analysis suggests specific dose reductions, as described in SmPC / prescribing information, led to decreases in the incidence and severity of treatment-related adverse events (AEs) in afatinib-treated patients without any apparent compromise in efficacy.
Smith & Nephew: Post-Operative Use of PICOTM Single Use Negative Pressure Wound Therapy Improves Predictability in Wound Healing and Reduces Complications Following Orthopaedic Surgery.
A Randomised Controlled Trial (RCT) of 220 patients undergoing primary hip or knee replacement compared the use of PICO, the novel Single use Negative Pressure Wound Therapy (NPWT) system, with standard dressings on closed surgical incisions. The research took place over a 12 month period at The Robert Jones and Agnes Hunt Orthopaedic Hospital NHS Foundation Trust (RJAH), Shropshire, UK. Results show significant reduction in; wound exudate distribution within the dressing, the number of dressing changes and extreme length of stay in hospital amongst those patients where PICO was applied.1
Myriad RBM's TruCulture(R) and Gene Expression Profiling Characterizes Immune Responses in Landmark Study Led by Institut Pasteur
(GLOBE NEWSWIRE) -- Myriad RBM, Inc., a wholly owned subsidiary of Myriad Genetics, Inc. (NASDAQ:MYGN) a global leader in personalized medicine, announced today that researchers from the Institut Pasteur have published new landmark research from the Milieu Interieur Project relating to the ability to perform standardized transcriptome profiling based upon a variety of immune stimuli in the August issue of Cell Reports. The study looked at the expression levels of different genes in 25 subjects following TruCulture incubation with twenty clinically relevant immune system stimulants. The research demonstrated that expression levels from as few as 44 of the 572 genes tested could segregate responses from the various stimuli and reveal variations in immune response. "We are excited by the results of this study which demonstrated that a relatively small subset of gene expression targets could explain the variability in immune response to different immune stimuli seen among patients," said Matthew Albert, co-coordinator of Milieu Interieur and director of the Immunobioology of Dendritic Cells Unit at the Institut Pasteur. "The ability of TruCulture to perform this analysis in an ex-vivo environment is truly unique making it an invaluable tool for assessing potential biomarkers relevant to immune response in patients." To perform the study, the researchers at the Institut Pasteur utilized Myriad RBM's TruCulture technology which is a proprietary blood collection and culturing system that allows researchers to perform ex-vivo immune system analysis. Unlike the current laboratory-based methods, TruCulture is deployed at the site of collection and therefore avoids variability from shipping and complex processing as well as the expense of a cell culture facility and staff.
Clinical trials and emerging research in radiation oncology to be featured at ASTRO’s Annual Meeting in Boston
ress program will highlight innovations in cancer care from 15 leading studies in five news briefings held live on-site and via webcastThe American Society for Radiation Oncology (ASTRO) announced today the press program for its 58th Annual Meeting, which includes multiple reports from phase III clinical trials, researchers from leading institutions in the U.S. and abroad, and examinations of a range of cancer types and patient populations. Researchers will share their findings in a series of briefings held on-site at the Boston Convention & Exhibition Center and webcast to registered press.
Skanska has signed a contract with Inspira Health Network to build a new hospital building in New Jersey, USA. The contract is worth USD 200M, about SEK 1.7 billion, which will be included in the order bookings for Skanska USA Building in the third quarter 2016.Skanska will build a 5-story, about 41,000 square-meter, hospital with 204 beds. The main tower consists of operating rooms, an emergency department, imaging suites, as well as administrative, dining and support services. The project also includes constructing a new central utility plant, which will provide electrical power, heating/hot water and chilled water.The new Inspira Health Network Medical Center will be built under the Integrated Project Delivery (IPD) approach, which brings together the client, designer and the builder to align stakeholders and streamline the execution of the project.
Electronic Health Record Data Can Help Determine Highest Risk of Early Death from Chemotherapy in Older Patients with Lymphoma
As published in JNCCN , a new Brown University study of registry data for older patients with diffuse large B-cell lymphoma treated with contemporary immunochemotherapy found opportunities to mitigate early death using key risk factors in decision-making and providing prophylactic administration of G-CSF; additional studies are warranted.FORT WASHINGTON, PA — Although diffuse large B-cell lymphoma (DLBCL) is a curable disease in most patients aged 65 years or older, these patients are also at higher risk of chemotherapy-related death within the first 30 days of treatment.To quantify the risk of early fatality and identify risk factors, researchers led by Adam J. Olszewski, MD, Brown University and Rhode Island Hospital, looked at Medicare claims linked to Surveillance, Epidemiology and End Results registry (SEER-Medicare) data for more than 5,500 patients, ages 65 and older, with DLBCL who were treated with contemporary immunochemotherapy—rituximab, cyclophosphamide, and vincristine in combination with doxorubicin, mitoxantrone, or etoposide. Their findings are published online in the September issue of JNCCN – Journal of the National Comprehensive Cancer Network . Complimentary access to the study is available until November 30, 2016.
Amgen to Highlight 19 Abstracts on Osteoporosis Disease State and Treatment at American Society for Bone and Mineral Research Annual Meeting
PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will present data from multiple studies for its investigational agent romosozumab and for Prolia® (denosumab) at the Annual Meeting of the American Society for Bone and Mineral Research (ASBMR) in Atlanta on Sept. 16-19, 2016. At the congress, Amgen will highlight a diverse set of data across its osteoporosis clinical programs, as well as real-world data that provide important insights on living with osteoporosis and underscore the Company's commitment to pioneering novel treatment options that can help reduce fracture risk.